Sign in to continue:

Thursday, July 30th, 2026

哈尔滨威帝电子重大资产重组内幕信息知情人买卖股票自查及核查意见报告

浙商证券核查哈尔滨威帝电子重组相关主体买卖股票情况报告——投资者详细解读

浙商证券核查哈尔滨威帝电子重组相关主体买卖股票情况报告——投资者详细解读

一、报告背景与核心内容

近日,浙商证券股份有限公司作为独立财务顾问,对哈尔滨威帝电子股份有限公司(以下简称“威帝股份”或“公司”)本次重大资产重组相关内幕信息知情人买卖公司股票的情况进行了全面核查。本次重组,公司拟以现金方式收购江苏智越天成企业管理有限公司100%股权及江苏玖星精密科技股份有限公司44.8506%股权。此次交易涉及多名自然人及相关法人机构,属于重大资产重组事项,具有高度敏感性,对公司股价或有较大影响。

二、内幕信息知情人股票交易自查期间、核查范围

  • 自查期间:2025年6月8日至2026年4月1日(即本次交易首次公告前六个月至重组报告书草案披露前一日)。
  • 核查范围:涵盖上市公司及其董高管、控股股东及实际控制人、交易对方、标的公司董高管、为本次交易提供服务的中介机构及其经办人,其他知情人及其直系亲属。

三、内幕信息知情人买卖股票详情及关键承诺

1. 相关自然人买卖威帝股份股票情况

  • 李新文:为上海久有私募基金管理有限公司业务总监李黎之父,在2025年12月11日至12月12日期间买入500股,卖出500股,期末持股为0。
  • 唐鲁秀:为其他知情人张金晶之母,在2026年1月29日至2月24日期间买入10,000股,卖出10,000股,期末持股为0。

相关当事人均出具书面声明及承诺,确认其买卖公司股票行为:

  • 无利用内幕信息或泄露内幕信息的行为;未建议他人买卖威帝股份股票。
  • 买卖行为系基于公开市场信息和个人判断,与本次重组无关。
  • 如买卖行为违反相关法律法规,愿将所得收益上缴公司。
  • 承诺在本次交易完成前或终止前,不再买卖威帝股份股票。

2. 相关法人机构买卖威帝股份股票情况

  • 浙商证券股份有限公司:自营账户在自查期间买入38,600股,卖出38,600股,期末持股为0。相关交易属于正常自营业务,包括ETF、LOF、组合投资、量化投资等,均在信息隔离墙制度下独立操作,不涉及内幕信息流转。

浙商证券声明已建立严格的信息隔离措施,确保投资银行、自营、资产管理等部门独立运作,控制内幕信息流转和使用,防范内幕交易发生,与本次重组无关联利益冲突。

四、独立财务顾问核查意见与结论

核查期间涉及买卖公司股票的自然人及法人均已出具声明和承诺,核查未发现存在利用内幕信息进行内幕交易的情形。相关主体所涉买卖行为不构成对本次重组事项的实质性法律障碍。

五、对投资者的影响与关注要点

  • 重组交易进展和内幕信息安全:此次核查进一步确保了重组进程的合规性与安全性,有助于增加市场对公司治理和信息披露的信心,降低监管风险。
  • 未出现重大内幕交易风险:尽管有极少数知情人及直系亲属发生过股票买卖,但均已说明与本次重组无关,且承诺如有违法所得将上缴公司。
  • 中介机构自营交易合规:浙商证券的相关自营交易均属于业务常规操作,不受内幕信息影响,进一步降低了相关利益冲突和合规风险。

投资者需持续关注后续重组事项进展及相关信息披露。任何有关内幕交易的新发现或监管动态,均可能对公司股价产生敏感影响。

六、结论

本次自查报告及核查意见表明,威帝股份此次重大资产重组事项在内幕信息管理及相关主体股票交易方面基本合规,不存在重大法律障碍。公司治理及信息披露规范性有助于维持市场信心。


免责声明:本文根据公开核查文件整理,仅供投资者参考,不构成任何投资建议。请投资者根据自身情况独立判断风险。公司后续进展及监管要求可能影响最终结果。


English Version
Zhejiang Securities’ Review of Harbin Weidi Electronics M&A-related Stock Transactions – Detailed Investor Report

Zhejiang Securities’ Review of Harbin Weidi Electronics M&A-related Stock Transactions – Detailed Investor Report

1. Background and Key Points

Zhejiang Securities, as the independent financial advisor, completed a thorough investigation into the stock transactions of insiders related to Harbin Weidi Electronics Co., Ltd.’s (hereinafter “Weidi Electronics” or “the Company”) major asset restructuring. The transaction involves the cash acquisition of 100% equity in Jiangsu Zhiyue Tiancheng Enterprise Management Co., Ltd. and 44.8506% equity in Jiangsu Jiuxing Precision Technology Co., Ltd. This constitutes a major asset restructuring and is highly price sensitive, potentially affecting the company’s share price.

2. Insider Stock Trading Investigation Period and Scope

  • Investigation period: June 8, 2025, to April 1, 2026 (six months prior to the first announcement of the transaction until the day before the restructuring report draft disclosure).
  • Scope: Includes the company and its directors/senior managers, controlling shareholders/actual controllers, transaction counterparties, directors/senior managers of the target companies, intermediaries and their staff, other informed parties, and direct relatives.

3. Detailed Insider Stock Transactions and Key Commitments

1. Natural Person Transactions

  • Li Xinwen: Father of Li Li (Business Director, Shanghai JiuYou Private Equity Fund Management), bought 500 shares and sold 500 shares between Dec 11-12, 2025; end-of-period holding: 0.
  • Tang Luxiu: Mother of other insider Zhang Jinjing, bought 10,000 shares and sold 10,000 shares between Jan 29-Feb 24, 2026; end-of-period holding: 0.

All parties provided written statements and commitments, confirming:

  • No insider information leakage or use; no advice to others to trade Weidi shares.
  • Trading was based on public market information and independent judgment, unrelated to the restructuring.
  • If found in violation, all profits to be handed over to the company.
  • Pledge not to trade Weidi shares until the deal is completed or terminated.

2. Legal Entity Transactions

  • Zhejiang Securities Co., Ltd.: Self-operated account bought and sold 38,600 shares during the investigation period, with zero end-of-period holdings. Transactions were routine self-operated business (ETF, LOF, portfolio, quant trading, etc.) and excluded from insider list restrictions. The company maintains strict information barriers, ensuring no improper flow of insider info.

Zhejiang Securities confirmed strict internal controls and information barriers to prevent insider trading and conflicts of interest. Their trading activities were unrelated to the restructuring.

4. Financial Advisor’s Opinion and Conclusion

All individuals/entities involved in share transactions have made statements and commitments; no improper insider trading was found. The behaviors of the relevant parties do not constitute a substantive legal obstacle to the restructuring.

5. Investor Impact and Focus Points

  • Progress and Insider Information Security: The investigation increases confidence in compliance and disclosure, reducing regulatory risk.
  • No Major Insider Trading Risks Identified: Limited transactions by insiders/relatives, all explained and committed to compliance. Any unlawful gains would be handed over to the company.
  • Compliance of Intermediary Proprietary Trading: Zhejiang Securities’ trades are routine, not influenced by insider information, reducing conflict-of-interest and compliance risk.

Investors should monitor further developments and disclosures. Any new findings or regulatory developments could materially impact the share price.

6. Conclusion

The self-examination report and review opinion indicate the restructuring is in compliance regarding insider information and related share trading. The company’s corporate governance and disclosure practices support market confidence.


Disclaimer: This article is based on public review documents and is for investor reference only. It does not constitute investment advice. Please assess risks independently. Future developments and regulatory requirements may affect outcomes.


View 威帝股份 Historical chart here



Zhejiang Medicine Co., Ltd. 2026 Q1 Financial Report: Revenue, Profit Decline and Key Shareholder Information

浙江医药股份有限公司2026年第一季度报告详解 业绩下滑引发投资者关注,维生素主力产品价格承压 浙江医药股份有限公司(...

Shanghai Construction Group 2025 Dividend Distribution Announcement – Cash Dividend Details and Tax Information

上海建工集团股份有限公司2025年年度权益分派实施公告详解 要点概览 分红方案获批:2025年度利润分配方案已于202...

衢州信安发展股份有限公司股份回购进展公告(2026年最新披露)

衢州信安发展股份有限公司股份回购进展公告深度解读 衢州信安发展股份有限公司发布股份回购进展公告,累计回购金额达4,8...